{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nRecent investigations into breast cancer have highlighted MIR4472-2 as a microRNA whose elevated expression is associated with enhanced tumor growth and the development of chemoresistance. In particular, studies have demonstrated that higher levels of MIR4472-2 correlate with larger tumor sizes and reduced sensitivity to chemotherapeutic agents, suggesting that this miRNA may influence key signaling pathways that control cell proliferation and survival."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nParallel research focusing on non-coding RNAs, such as the long non-coding RNA RP11-551L14.4, underscores the intricate regulatory networks present in breast cancer. Although the study on RP11-551L14.4 did not directly address MIR4472-2, it supports the notion that complex interactions among various non-coding RNAs—including miRNAs like MIR4472-2—may converge to modulate gene expression and impact cancer progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nIn summary, MIR4472-2 emerges as a candidate regulator in breast cancer that is potentially pivotal in promoting tumor aggressiveness and chemoresistance. While its precise molecular mechanisms remain to be fully elucidated, its association with adverse tumor characteristics and the broader context of non-coding RNA-mediated regulation highlight the need for further studies to determine its role in the pathological processes of breast cancer."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yan Li, Ya-Wen Wang, Xu Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-4472 Promotes Tumor Proliferation and Aggressiveness in Breast Cancer by Targeting RGMA and Inducing EMT."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Breast Cancer (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.clbc.2019.08.010"}], "href": "https://doi.org/10.1016/j.clbc.2019.08.010"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31899158"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31899158"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Bin Wang, Hang Chen, Rui Yang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LncRNA RP11-551L14.4 suppresses breast cancer development by inhibiting the expression of miR-4472."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PeerJ (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.7717/peerj.14482"}], "href": "https://doi.org/10.7717/peerj.14482"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "36523479"}], "href": "https://pubmed.ncbi.nlm.nih.gov/36523479"}]}]}]}